N17

General Information


DRACP ID  DRACP02515

Peptide Name   N17

Sequence  KILRGVSKKIMRTFLRR

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma Not active up to 100μg/ml MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: <5% Hemolysis=100 µg/ml

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02515

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C94H172N32O20S

Absent amino acids  ACDEHNPQWY

Common amino acids  R

Mass  238822

Pl  12.99

Basic residues  7

Acidic residues  0

Hydrophobic residues  6

Net charge  7

Boman Index  -5231

Hydrophobicity  -35.88

Aliphatic Index  108.82

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 17389605

Title  Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens

Doi 10.1074/jbc.M608920200

Year  2007

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_5049

DRACP is developed by Dr.Zheng's team.